Selected research
Market Structure
Global Follicular Lymphoma Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Follicular Lymphoma Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Follicular Lymphoma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Follicular Lymphoma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Follicular Lymphoma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Follicular Lymphoma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Follicular Lymphoma Drugs include Eisai, Teva, Novartis, Roche, Pfizer, FOSUNKite, Bayer, Beigene and Secura Bio, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Follicular Lymphoma Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Follicular Lymphoma Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Follicular Lymphoma Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Follicular Lymphoma Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Follicular Lymphoma Drugs Segment by Company
Eisai
Teva
Novartis
Roche
Pfizer
FOSUNKite
Bayer
Beigene
Secura Bio
MundiPharma
JW Therapeutics
Gilead Sciences
Epizyme
Eagle Pharmaceuticals
Bristol-Myers Squibb
Acrotech Biopharma
Follicular Lymphoma Drugs Segment by Type
Anti-CD20 mAbs
Kinase Inhibitor
Chemotherapy Agents
Others
Follicular Lymphoma Drugs Segment by Application
Injection
Oral
Follicular Lymphoma Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Follicular Lymphoma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Follicular Lymphoma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Follicular Lymphoma Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Follicular Lymphoma Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Follicular Lymphoma Drugs industry.
Chapter 3: Detailed analysis of Follicular Lymphoma Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Follicular Lymphoma Drugsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Anti-CD20 mAbs
- Kinase Inhibitor
- Chemotherapy Agents
- Others
Applications
- Injection
- Oral
Companies covered
- Eisai
- Teva
- Novartis
- Roche
- Pfizer
- FOSUNKite
- Bayer
- Beigene
- Secura Bio
- MundiPharma
- JW Therapeutics
- Gilead Sciences
- Epizyme
- Eagle Pharmaceuticals
- Bristol-Myers Squibb
- Acrotech Biopharma
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Follicular Lymphoma Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Anti-CD20 mAbs
- 1.2.3 Kinase Inhibitor
- 1.2.4 Chemotherapy Agents
- 1.2.5 Others
- 1.3 Market Analysis by Application
- 1.3.1 Global Follicular Lymphoma Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Injection
- 1.3.3 Oral
- 1.4 Global Market Growth Prospects
- 1.5 Global Follicular Lymphoma Drugs Growth Trends by Region
- 1.5.1 Global Follicular Lymphoma Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Follicular Lymphoma Drugs Market Size by Region (2021-2026)
- 1.5.3 Follicular Lymphoma Drugs Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Follicular Lymphoma Drugs Market Dynamics
- 2.1 Follicular Lymphoma Drugs Industry Trends
- 2.2 Follicular Lymphoma Drugs Industry Drivers
- 2.3 Follicular Lymphoma Drugs Industry Opportunities and Challenges
- 2.4 Follicular Lymphoma Drugs Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Follicular Lymphoma Drugs Revenue by Company (2021-2026)
- 3.2 Global Follicular Lymphoma Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Follicular Lymphoma Drugs Key Company Head office and Area Served
- 3.4 Global Follicular Lymphoma Drugs Company, Product Type & Application
- 3.5 Global Follicular Lymphoma Drugs Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Follicular Lymphoma Drugs Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Follicular Lymphoma Drugs Players Market Share by Revenue in 2025
- 3.6.3 2025 Follicular Lymphoma Drugs Tier 1, Tier 2, and Tier 3
4 Follicular Lymphoma Drugs Market by Type
- 4.1 Global Follicular Lymphoma Drugs Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Follicular Lymphoma Drugs Market Size by Type (2021-2032)
- 4.3 Global Follicular Lymphoma Drugs Market Size Share by Type (2021-2032)
5 Follicular Lymphoma Drugs Market by Application
- 5.1 Global Follicular Lymphoma Drugs Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Follicular Lymphoma Drugs Market Size by Application (2021-2032)
- 5.3 Global Follicular Lymphoma Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Eisai
- 6.1.1 Eisai Company Information
- 6.1.2 Eisai Business Overview
- 6.1.3 Eisai Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Eisai Follicular Lymphoma Drugs Product Portfolio
- 6.1.5 Eisai Recent Developments
- 6.2 Teva
- 6.2.1 Teva Company Information
- 6.2.2 Teva Business Overview
- 6.2.3 Teva Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Teva Follicular Lymphoma Drugs Product Portfolio
- 6.2.5 Teva Recent Developments
- 6.3 Novartis
- 6.3.1 Novartis Company Information
- 6.3.2 Novartis Business Overview
- 6.3.3 Novartis Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Novartis Follicular Lymphoma Drugs Product Portfolio
- 6.3.5 Novartis Recent Developments
- 6.4 Roche
- 6.4.1 Roche Company Information
- 6.4.2 Roche Business Overview
- 6.4.3 Roche Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Roche Follicular Lymphoma Drugs Product Portfolio
- 6.4.5 Roche Recent Developments
- 6.5 Pfizer
- 6.5.1 Pfizer Company Information
- 6.5.2 Pfizer Business Overview
- 6.5.3 Pfizer Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Pfizer Follicular Lymphoma Drugs Product Portfolio
- 6.5.5 Pfizer Recent Developments
- 6.6 FOSUNKite
- 6.6.1 FOSUNKite Company Information
- 6.6.2 FOSUNKite Business Overview
- 6.6.3 FOSUNKite Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 FOSUNKite Follicular Lymphoma Drugs Product Portfolio
- 6.6.5 FOSUNKite Recent Developments
- 6.7 Bayer
- 6.7.1 Bayer Company Information
- 6.7.2 Bayer Business Overview
- 6.7.3 Bayer Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Bayer Follicular Lymphoma Drugs Product Portfolio
- 6.7.5 Bayer Recent Developments
- 6.8 Beigene
- 6.8.1 Beigene Company Information
- 6.8.2 Beigene Business Overview
- 6.8.3 Beigene Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Beigene Follicular Lymphoma Drugs Product Portfolio
- 6.8.5 Beigene Recent Developments
- 6.9 Secura Bio
- 6.9.1 Secura Bio Company Information
- 6.9.2 Secura Bio Business Overview
- 6.9.3 Secura Bio Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Secura Bio Follicular Lymphoma Drugs Product Portfolio
- 6.9.5 Secura Bio Recent Developments
- 6.10 MundiPharma
- 6.10.1 MundiPharma Company Information
- 6.10.2 MundiPharma Business Overview
- 6.10.3 MundiPharma Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 MundiPharma Follicular Lymphoma Drugs Product Portfolio
- 6.10.5 MundiPharma Recent Developments
- 6.11 JW Therapeutics
- 6.11.1 JW Therapeutics Company Information
- 6.11.2 JW Therapeutics Business Overview
- 6.11.3 JW Therapeutics Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 JW Therapeutics Follicular Lymphoma Drugs Product Portfolio
- 6.11.5 JW Therapeutics Recent Developments
- 6.12 Gilead Sciences
- 6.12.1 Gilead Sciences Company Information
- 6.12.2 Gilead Sciences Business Overview
- 6.12.3 Gilead Sciences Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Gilead Sciences Follicular Lymphoma Drugs Product Portfolio
- 6.12.5 Gilead Sciences Recent Developments
- 6.13 Epizyme
- 6.13.1 Epizyme Company Information
- 6.13.2 Epizyme Business Overview
- 6.13.3 Epizyme Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Epizyme Follicular Lymphoma Drugs Product Portfolio
- 6.13.5 Epizyme Recent Developments
- 6.14 Eagle Pharmaceuticals
- 6.14.1 Eagle Pharmaceuticals Company Information
- 6.14.2 Eagle Pharmaceuticals Business Overview
- 6.14.3 Eagle Pharmaceuticals Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Eagle Pharmaceuticals Follicular Lymphoma Drugs Product Portfolio
- 6.14.5 Eagle Pharmaceuticals Recent Developments
- 6.15 Bristol-Myers Squibb
- 6.15.1 Bristol-Myers Squibb Company Information
- 6.15.2 Bristol-Myers Squibb Business Overview
- 6.15.3 Bristol-Myers Squibb Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Bristol-Myers Squibb Follicular Lymphoma Drugs Product Portfolio
- 6.15.5 Bristol-Myers Squibb Recent Developments
- 6.16 Acrotech Biopharma
- 6.16.1 Acrotech Biopharma Company Information
- 6.16.2 Acrotech Biopharma Business Overview
- 6.16.3 Acrotech Biopharma Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.16.4 Acrotech Biopharma Follicular Lymphoma Drugs Product Portfolio
- 6.16.5 Acrotech Biopharma Recent Developments
7 North America
- 7.1 North America Follicular Lymphoma Drugs Market Size (2021-2032)
- 7.2 North America Follicular Lymphoma Drugs Market Size by Type
- 7.2.1 North America Follicular Lymphoma Drugs Market Size by Type (2021-2026)
- 7.2.2 North America Follicular Lymphoma Drugs Market Size by Type (2027-2032)
- 7.2.3 North America Follicular Lymphoma Drugs Market Share by Type (2021-2032)
- 7.3 North America Follicular Lymphoma Drugs Market Size by Application
- 7.3.1 North America Follicular Lymphoma Drugs Market Size by Application (2021-2026)
- 7.3.2 North America Follicular Lymphoma Drugs Market Size by Application (2027-2032)
- 7.3.3 North America Follicular Lymphoma Drugs Market Share by Application (2021-2032)
- 7.4 North America Follicular Lymphoma Drugs Market Size by Country
- 7.4.1 North America Follicular Lymphoma Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Follicular Lymphoma Drugs Market Size by Country (2021-2026)
- 7.4.3 North America Follicular Lymphoma Drugs Market Size by Country (2027-2032)
- 7.4.4 North America Follicular Lymphoma Drugs Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Follicular Lymphoma Drugs Market Size (2021-2032)
- 8.2 Europe Follicular Lymphoma Drugs Market Size by Type
- 8.2.1 Europe Follicular Lymphoma Drugs Market Size by Type (2021-2026)
- 8.2.2 Europe Follicular Lymphoma Drugs Market Size by Type (2027-2032)
- 8.2.3 Europe Follicular Lymphoma Drugs Market Share by Type (2021-2032)
- 8.3 Europe Follicular Lymphoma Drugs Market Size by Application
- 8.3.1 Europe Follicular Lymphoma Drugs Market Size by Application (2021-2026)
- 8.3.2 Europe Follicular Lymphoma Drugs Market Size by Application (2027-2032)
- 8.3.3 Europe Follicular Lymphoma Drugs Market Share by Application (2021-2032)
- 8.4 Europe Follicular Lymphoma Drugs Market Size by Country
- 8.4.1 Europe Follicular Lymphoma Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Follicular Lymphoma Drugs Market Size by Country (2021-2026)
- 8.4.3 Europe Follicular Lymphoma Drugs Market Size by Country (2027-2032)
- 8.4.4 Europe Follicular Lymphoma Drugs Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Follicular Lymphoma Drugs Market Size (2021-2032)
- 9.2 China Follicular Lymphoma Drugs Market Size by Type
- 9.2.1 China Follicular Lymphoma Drugs Market Size by Type (2021-2026)
- 9.2.2 China Follicular Lymphoma Drugs Market Size by Type (2027-2032)
- 9.2.3 China Follicular Lymphoma Drugs Market Share by Type (2021-2032)
- 9.3 China Follicular Lymphoma Drugs Market Size by Application
- 9.3.1 China Follicular Lymphoma Drugs Market Size by Application (2021-2026)
- 9.3.2 China Follicular Lymphoma Drugs Market Size by Application (2027-2032)
- 9.3.3 China Follicular Lymphoma Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Follicular Lymphoma Drugs Market Size (2021-2032)
- 10.2 Asia Follicular Lymphoma Drugs Market Size by Type
- 10.2.1 Asia Follicular Lymphoma Drugs Market Size by Type (2021-2026)
- 10.2.2 Asia Follicular Lymphoma Drugs Market Size by Type (2027-2032)
- 10.2.3 Asia Follicular Lymphoma Drugs Market Share by Type (2021-2032)
- 10.3 Asia Follicular Lymphoma Drugs Market Size by Application
- 10.3.1 Asia Follicular Lymphoma Drugs Market Size by Application (2021-2026)
- 10.3.2 Asia Follicular Lymphoma Drugs Market Size by Application (2027-2032)
- 10.3.3 Asia Follicular Lymphoma Drugs Market Share by Application (2021-2032)
- 10.4 Asia Follicular Lymphoma Drugs Market Size by Country
- 10.4.1 Asia Follicular Lymphoma Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Follicular Lymphoma Drugs Market Size by Country (2021-2026)
- 10.4.3 Asia Follicular Lymphoma Drugs Market Size by Country (2027-2032)
- 10.4.4 Asia Follicular Lymphoma Drugs Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Follicular Lymphoma Drugs Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Follicular Lymphoma Drugs Market Size by Type
- 11.2.1 South America, Middle East & Africa Follicular Lymphoma Drugs Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Follicular Lymphoma Drugs Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Follicular Lymphoma Drugs Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Follicular Lymphoma Drugs Market Size by Application
- 11.3.1 South America, Middle East & Africa Follicular Lymphoma Drugs Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Follicular Lymphoma Drugs Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Follicular Lymphoma Drugs Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Follicular Lymphoma Drugs Market Size by Country
- 11.4.1 South America, Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Follicular Lymphoma Drugs Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst